Tags

Type your tag names separated by a space and hit enter

GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation.
Biochem Pharmacol. 2009 Oct 01; 78(7):863-72.BP

Abstract

The vagus nerve can limit inflammation via the alpha7 nicotinic acetylcholine receptor (alpha7nAChR). Selective pharmacological stimulation of the alpha7nAChR may have therapeutic potential for the treatment of inflammatory conditions. We determined the anti-inflammatory potential of GTS-21, an alpha7nAChR-selective partial agonist, on primary human leukocytes and compared it with nicotine, the nAChR agonist widely used for research into the anti-inflammatory effects of alpha7nAChR stimulation. Furthermore, we investigated whether the effects of both nicotinic agonists were restricted to specific Toll-like receptors (TLRs) stimulated and explored the mechanism behind the anti-inflammatory effect of GTS-21. GTS-21 and nicotine inhibited the release of pro-inflammatory cytokines in peripheral blood mononuclear cells (PBMCs), monocytes and whole blood independent of the TLR stimulated, with higher potency/efficacy for GTS-21 compared to nicotine. The anti-inflammatory cytokine IL-10 was relatively unaffected by both nicotinic agonists. The effects of GTS-21 and nicotine could not be reversed by nAChR antagonists, while the JAK2 inhibitor AG490 abolished the anti-inflammatory effects. GTS-21 downregulated monocyte cell-surface expression of TLR2, TLR4 and CD14. qPCR analysis demonstrated that the anti-inflammatory effect of GTS-21 is mediated at the transcriptional level and involves JAK2-STAT3 activation. In conclusion, GTS-21 has a profound anti-inflammatory effect in human leukocytes and that GTS-21 is more potent/efficacious than nicotine. The absence of a blocking effect of nAChR antagonists in human leukocytes might indicate different pharmacological properties of the alpha7nAChR in human leukocytes compared to other cell types. GTS-21 may be promising from a therapeutic perspective because of its suitability for human use.

Authors+Show Affiliations

Department of Intensive Care Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19576181

Citation

Kox, Matthijs, et al. "GTS-21 Inhibits Pro-inflammatory Cytokine Release Independent of the Toll-like Receptor Stimulated Via a Transcriptional Mechanism Involving JAK2 Activation." Biochemical Pharmacology, vol. 78, no. 7, 2009, pp. 863-72.
Kox M, van Velzen JF, Pompe JC, et al. GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. Biochem Pharmacol. 2009;78(7):863-72.
Kox, M., van Velzen, J. F., Pompe, J. C., Hoedemaekers, C. W., van der Hoeven, J. G., & Pickkers, P. (2009). GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. Biochemical Pharmacology, 78(7), 863-72. https://doi.org/10.1016/j.bcp.2009.06.096
Kox M, et al. GTS-21 Inhibits Pro-inflammatory Cytokine Release Independent of the Toll-like Receptor Stimulated Via a Transcriptional Mechanism Involving JAK2 Activation. Biochem Pharmacol. 2009 Oct 1;78(7):863-72. PubMed PMID: 19576181.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. AU - Kox,Matthijs, AU - van Velzen,Jeroen F, AU - Pompe,Jan C, AU - Hoedemaekers,Cornelia W, AU - van der Hoeven,Johannes G, AU - Pickkers,Peter, Y1 - 2009/07/01/ PY - 2009/04/22/received PY - 2009/06/12/revised PY - 2009/06/23/accepted PY - 2009/7/7/entrez PY - 2009/7/7/pubmed PY - 2009/9/22/medline SP - 863 EP - 72 JF - Biochemical pharmacology JO - Biochem Pharmacol VL - 78 IS - 7 N2 - The vagus nerve can limit inflammation via the alpha7 nicotinic acetylcholine receptor (alpha7nAChR). Selective pharmacological stimulation of the alpha7nAChR may have therapeutic potential for the treatment of inflammatory conditions. We determined the anti-inflammatory potential of GTS-21, an alpha7nAChR-selective partial agonist, on primary human leukocytes and compared it with nicotine, the nAChR agonist widely used for research into the anti-inflammatory effects of alpha7nAChR stimulation. Furthermore, we investigated whether the effects of both nicotinic agonists were restricted to specific Toll-like receptors (TLRs) stimulated and explored the mechanism behind the anti-inflammatory effect of GTS-21. GTS-21 and nicotine inhibited the release of pro-inflammatory cytokines in peripheral blood mononuclear cells (PBMCs), monocytes and whole blood independent of the TLR stimulated, with higher potency/efficacy for GTS-21 compared to nicotine. The anti-inflammatory cytokine IL-10 was relatively unaffected by both nicotinic agonists. The effects of GTS-21 and nicotine could not be reversed by nAChR antagonists, while the JAK2 inhibitor AG490 abolished the anti-inflammatory effects. GTS-21 downregulated monocyte cell-surface expression of TLR2, TLR4 and CD14. qPCR analysis demonstrated that the anti-inflammatory effect of GTS-21 is mediated at the transcriptional level and involves JAK2-STAT3 activation. In conclusion, GTS-21 has a profound anti-inflammatory effect in human leukocytes and that GTS-21 is more potent/efficacious than nicotine. The absence of a blocking effect of nAChR antagonists in human leukocytes might indicate different pharmacological properties of the alpha7nAChR in human leukocytes compared to other cell types. GTS-21 may be promising from a therapeutic perspective because of its suitability for human use. SN - 1873-2968 UR - https://www.unboundmedicine.com/medline/citation/19576181/GTS_21_inhibits_pro_inflammatory_cytokine_release_independent_of_the_Toll_like_receptor_stimulated_via_a_transcriptional_mechanism_involving_JAK2_activation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-2952(09)00567-X DB - PRIME DP - Unbound Medicine ER -